OneSource Specialty Pharma FY26 Financial Results

Revenue: Rs 1,421.6 crore | Adjusted PAT: Rs 73.9 crore

Reader Takeaway: Revenue dip due to regulatory deferrals; management maintains strong FY28 outlook driven by US$100M capacity expansion.

What just happened

OneSource Specialty Pharma reported FY26 revenue of Rs 1,421.6 crore, representing a 2% decline compared to the previous year. EBITDA was recorded at Rs 304.2 crore with a margin of 21%. The company reported an Adjusted PAT of Rs 73.9 crore and an Adjusted EPS of Rs 6.5. The management stated the revenue decline was primarily due to regulatory delays for a semaglutide product in Canada, resulting in deferred rather than lost revenue.

Why this matters

The company is currently in a major expansion phase. It has committed 80% of its planned US$100 million capital expenditure budget toward increasing cartridge manufacturing capacity. A new high-capacity filling line is scheduled to become operational in Q2FY27, which is expected to support future growth in the Drug-Device (DDC) platform.

Strategic Outlook

Despite the FY26 revenue dip, leadership reaffirmed its FY28 guidance of US$400 million in revenue and a 40% EBITDA margin. The company is betting on its multi-modality platform, which covers biologics, sterile injectables, and oral technologies, to capture increasing global demand for specialty CDMO services.

Governance and Audit

The company transitioned its statutory auditors from Deloitte to BSR (KPMG) during the fiscal year to ensure audit rotation compliance. Additionally, the firm has seen five credit rating upgrades since listing, successfully reducing its borrowing costs to below 9%.

What to track next

Investors should monitor the Q2FY27 commercialization of the new cartridge filling line, the progress of GLP-1 regulatory approvals, and the conversion of the biologics project pipeline into long-term commercial supply agreements.